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Abstract
Background: Evidence suggests that risk of colorectal and prostate cancer is increased among those with a family
history of the same disease, particularly among first-degree relatives. However, the aggregation of colorectal and
prostate cancer within families has not been well investigated.
Methods: Analyses were conducted among participants of the Women’s Health Initiative (WHI) observational
cohort, free of cancer at the baseline examination. Subjects were followed for colorectal cancer through August
31st, 2009. A Cox-proportional hazards regression modeling approach was used to estimate risk of colorectal cancer
associated with a family history of prostate cancer, colorectal cancer and both cancers among first-degree relatives
of all participants and stratified by race (African American vs. White).
Results: Of 75,999 eligible participants, there were 1122 colorectal cancer cases diagnosed over the study period. A
family history of prostate cancer alone was not associated with an increase in colorectal cancer risk after adjustment
for confounders (aHR =0.94; 95% CI =0.76, 1.15). Separate analysis examining the joint impact, a family history of
both colorectal and prostate cancer was associated with an almost 50% increase in colorectal cancer risk (aHR = 1.
48; 95% CI = 1.04, 2.10), but similar to those with a family history of colorectal cancer only (95% CI = 1.31; 95%
CI = 1.11, 1.54).
Conclusions: Our findings suggest risk of colorectal cancer is increased similarly among women with colorectal
cancer only and among those with both colorectal and prostate cancer diagnosed among first-degree family
members. Future studies are needed to determine the relative contribution of genes and shared environment to
the risk of both cancers.
Background
Colorectal cancer is both the 3rd most common invasive
cancer diagnosed in the United States (U.S.), and 2nd
most common cause of cancer mortality with a pre-
dicted 135,430 new cases diagnosed and 50,260 deaths
in 2017 [1]. Prostate cancer is the most common cancer
diagnosed among U.S. men with an estimated 161,360
cases and the 2nd leading cause of cancer mortality in
men with 26,730 attributed deaths [1]. A positive family
history of the same cancer is an important risk factor for
both cancers, particularly when it is diagnosed in a first-
degree family member [2–7]. Risk increases with an
increasing number of affected relatives and is inversely
associated with the age at diagnosis of affected relatives
[2, 5, 8–12]. It is estimated that 3–6% of colorectal
cancers may be attributed to rarer familial syndromes,
[13] including, but not limited to, germline mutations in
MSH2, MSH6, MLH1, and PMS2 in Hereditary Non-
Polyposis Colorectal Cancer (HNPCC) or Lynch syn-
drome, APC in Familial Adenomatous Polyposis (FAP)
and STK11 in Peutz-Jeghers syndrome (PJS) [14]. These
syndromes carry a lifetime risk of developing colorectal
cancer of up to 90% [15]. The remaining 20–30% of fa-
milial cases may be attributed to more common genes of
* Correspondence: dimmerj@karmanos.org
1Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA
2Department of Oncology, Wayne State University School of Medicine,
Detroit, Michigan 48201, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Beebe-Dimmer et al. BMC Cancer  (2017) 17:848 
DOI 10.1186/s12885-017-3873-5
lower penetrance, [15] potentially interacting with envir-
onmental factors. In contrast, very few genes have been
consistently reported in familial and hereditary prostate
cancer apart from BRCA 1 and BRCA2 as well as
HOXB13 [16–19]. This is despite the fact that inherited
predisposition is predicted to account for 30–35% of
prostate cancers [20].
Aggregation of colorectal and prostate cancer within
families has not been as thoroughly investigated. Epide-
miologic studies investigating the clustering of these
cancers within families are conducted in populations of
primarily European descent [21–26], few with an
adequate number of minority patients to address racial
or ethnic differences in risk associated with clustering of
these cancers in families. The rationale for studies fo-
cused on clustering of these two tumors within families
is partially driven by a similar underlying biology focused
on exposure to adipokines (leptin and adiponectin), in-
sulin and insulin-like growth factors, having mitogenic
and potentially genotoxic effects on target tissues. The
aggregation of colorectal and prostate cancer within
families is likely due to a combination of both genes and
shared environment, with environmental exposures oc-
curring earlier in life perhaps more important. Similarly
to our current knowledge of the contribution of genet-
ics, a number of lifestyle and medical risk factors have
been identified in colorectal cancer while very few estab-
lished risk factors for prostate cancer have been identi-
fied apart from family history, age and African American
race. Lastly, there are distinct racial differences in risk
and survival for both cancers. African Americans are
approximately 20% more likely to be diagnosed with
colorectal cancer and 50% more likely to die from the
disease compared to their Non-Hispanic white counter-
parts. Likewise, African American men are approxi-
mately 60% more likely to be diagnosed with prostate
cancer and 2.5 times more likely to die compared to
white men [27].
The current study evaluates the impact of a family
history of prostate cancer and aggregation of prostate
and colorectal cancer among first-degree relatives on
risk of colorectal cancer in the Women’s Health Initiative
Observational Study (WHI OS). Any evidence of cluster-
ing of these two cancers within close family members
would have significant clinical implications suggesting that
physicians should consider a family history of other
cancers in addition to colorectal cancer and recommend
earlier and more aggressive screening among women with
a positive family history. Colonoscopy screening is an
effective tool in reducing both colorectal cancer incidence
and mortality. For individuals with a family history of
colorectal cancer or adenomatous polyps in a first degree
relative diagnosed before age 60 years or multiple first de-
gree relatives diagnosed at any age (excluding suspected
familial cancer syndromes), the American Cancer Society
recommends colonoscopy screening to begin at age 40 or
10 years prior to the age at diagnosis of the youngest
affected relative, whichever comes first and should occur
every 5 years thereafter.. If family members are diagnosed
after age 60 years, screening is recommended to begin at
age 40 with repeat colonscopy every 10 years [28].
Subjects and methods
The WHI consists of several clinical trials and an obser-
vational cohort with over 168,000 U.S. healthy, postmen-
opausal women aged 50 to 79 enrolled with active
follow-up of living participants. The study details of the
WHI have been previously published [29–32]. The WHI
initially began as a randomized, placebo-controlled clin-
ical trial of treatment with estrogen and progesterone to
reduce the risk of coronary artery disease and a random-
ized, controlled clinical trial of a low-fat diet compared
to a usual diet on risk of breast and colorectal cancers
and coronary heart disease in postmenopausal women.
Any woman who was unwilling or ineligible to partici-
pate in the clinical trials was given an opportunity to
participate in the OS. Detailed information on demo-
graphics, personal medical history, and family medical
history, lifestyle and behavioral risk factors was collected
during a baseline interview on all OS participants.
The WHI OS study enrolled 93,676 postmenopausal
women through 40 clinical centers in the United
States between October 1, 1993 and December 31,
1998. The WHI OS protocol was reviewed by the In-
stitutional Review Board at each center and informed
consent was obtained from each participant locally.
Each participant completed an interview and physical
examination at baseline and at 3 years. Women were
deemed ineligible to participate in the OS at baseline
if they had a medical history which would impact
participation or predicted mortality within 3 years of
the baseline exam [29]. Annual questionnaires were
mailed to participants to obtain follow-up data fo-
cused primarily on changes in medical history and in
health behaviors. Colorectal cancers were verified
using medical records and pathology was reviewed
centrally by trained WHI physician adjudicators [32].
For the current study, women with any prevalent can-
cer at the baseline interview (n = 11,678), or those
women whose colorectal cancer was ascertained by
death certificate only (n = 97) were excluded (Fig. 1).
In addition, we excluded women who had missing
information on family history of either colorectal
cancer (n = 3363) or prostate cancer (n = 1912), as
well as women with an unknown period of follow-up
(n = 627). Follow-up documentation of incident
colorectal cancers was conducted through August
31st, 2009.
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Baseline data collection
At baseline, all participants had height, weight, waist and
hip circumference, and blood pressure measured, and
their body mass index (BMI) in kg/m2, calculated from
measures of weight and height. Participants also com-
pleted a standardized self-administered questionnaire
collecting information on demographics (including self-
reported race), occupation, lifestyle risk factors for vari-
ous chronic diseases (i.e., smoking, alcohol consumption
and physical activity), reproductive and medical history,
medication use and cancer screening behavior.
All participants were asked about their family medical
history including cancer diagnoses among close relatives.
The most detailed cancer family history data gathered
from women were for colorectal and breast cancer, pri-
marily due to the impact of these cancers on morbidity
and mortality, as well as their inclusion as secondary
end points in one or more of the clinical trial compo-
nents. For both of these cancers, the number of affected
first-degree relatives was recorded, the approximate age
at diagnosis for each affected relative, as well as the
relationship to the participant. For other cancers like
prostate cancer (endometrial, cervical and ovarian can-
cers), only the number of affected first-degree, full-blood
relatives was recorded. Data on half-siblings were not
collected.
Statistical analysis
All analyses were conducted using Statistical Analysis Sys-
tems software (SAS Inc. v.9.3, Cary, NC). Descriptive statis-
tics were used to characterize the baseline characteristics
of the study population including age, race/ethnicity,
education, WHI region, BMI, waist circumference,
smoking history, physical activity (in metabolic equiva-
lent [or MET] hours per week), alcohol intake, aspirin
use, hormone therapy use, insurance coverage, history
of diabetes, family history of other cancers (non-colo-
rectal, non-prostate), colorectal cancer screening within
previous 5 years, and general health. Differences in the
distribution of baseline characteristics between colorec-
tal cancer cases and non-cases were evaluated separ-
ately using chi-square tests and the associated p-values.
P-values of less than 0.05 were considered statistically
significant. Cox proportional hazards regression was
used to estimate hazard ratios (aHR) and 95% confi-
dence intervals (CI) for colorectal cancer associated
with having a family history of colorectal cancer and/or
prostate cancer with adjustment for important
confounders. Significant baseline characteristics were
included individually in preliminary regression models.
Of those characteristics, if their inclusion in the model
changed the hazard ratios related to family history of
either prostate or colorectal cancer by ≥10%, then these
characteristics were considered important confounding
variables. Models were generated for all participants
combined as well as stratified by race, and for the latter
analysis, participants of either non-white, non-African
American were excluded. For all analyses, family history
was restricted to first-degree, full blood relatives. As
adjustment for some baseline characteristics such as
number of first degree relatives, hormone replacement
therapy use, diabetes, waist circumference, physical ac-
tivity, smoking and aspirin use did not appreciably
change risk estimates, final models included mutual ad-
justment for family history of colorectal cancer, pros-
tate cancer, family history of other cancers, as well as
age, race, and colonoscopy screening history.
Results
Baseline characteristics of the 75,999 women included in
the study are summarized in Table 1. We identified 1122
incident colorectal cancer cases during follow-up of par-
ticipants with a median number of years of follow-up in
the cohort of 14.6 years (InterQuartile Range = 8.5, 16.2)
These cases were older at time of baseline survey
(median age 66 v. 63 years; p < 0.0001), and were more
likely than non-cases to be non-Hispanic white (85.0% v.
83.2%; p = 0.008), obese (28.6% v. 24.2%; p < 0.0001),
have a greater waist circumference (p < 0.0001), a history
of smoking (50.9% v. 47.8%; p = 0.04), and diabetes (7.6%
v. 5.3%; 0.0008). Cases were less likely to have had a
colonoscopy within 5 years of baseline interview (29.9%
v. 33.5%; p = 0.03), and less likely to have used hormone
replacement therapy (61.6% v. 69.5%; p < 0.0001).
Fig. 1 Women’s Health Initiative (WHI) Observational Study (OS)
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Table 1 Baseline characteristics of Women Participating in the WHI OS
Colorectal cancer cases Non-cases
Characteristic N (%)a N (%)a p-valueb
Total population 1122 1.5 74,877 98.5
Age at baseline
< 60 227 20.2 24,900 33.3 < 0.0001
60–69 529 47.1 32,959 44.0
> = 70 366 32.6 17,018 22.7
Age at diagnosis
50–59 55 4.9 –
60–69 296 26.4 –
70–79 518 46.2 –
80+ 253 22.5 –
Race/Ethnicity 0.008
Non-Hispanic White 954 85.0 62,296 83.2
Black 98 8.7 5930 7.9
Other 68 6.1 6449 8.6
Unknown 2 0.2 202 0.3
Education 0.63
No High school diploma 49 4.4 3668 4.9
High school diploma/GED 176 15.7 12,045 16.1
College graduate or above 890 79.3 58,560 78.2
Unknown 7 0.6 604 0.8
Region 0.005
Northeast 283 25.2 17,421 23.3
South 236 21.0 19,185 25.6
Midwest 251 22.4 16,427 21.9
West 352 31.4 21,844 29.2
Body mass index (kg/m2) 0.0003
Normal weight (<25.0) 401 35.7 30,664 41.0
Overweight (25.0–29.9) 386 34.4 25,238 33.7
Obese (> = 30.0) 321 28.6 18,110 24.2
Unknown 14 1.2 865 1.2
Waist (cm) < 0.0001
≤ 75 210 18.7 20,114 26.9
75.1–82.5 262 23.4 17,961 24.0
82.6–92.5 282 25.1 18,111 24.2
> 92.5 364 32.4 18,372 24.5
Unknown 4 0.4 319 0.4
Physical activity (MET-hours/week) 0.10
≤ 3.5 320 28.5 19,320 25.8
3.5+ − 10 270 24.1 17,985 24.0
10+ − 20 272 24.2 18,291 24.4
> 20 249 22.2 18,551 24.8
Unknown 11 1.0 730 1.0
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Table 1 Baseline characteristics of Women Participating in the WHI OS (Continued)
Colorectal cancer cases Non-cases
Characteristic N (%)a N (%)a p-valueb
Smoking 0.04
Never 540 48.1 38,087 50.9
Former 486 43.3 31,334 41.8
Current 85 7.6 4529 6.0
Unknown 11 1.0 927 1.2
Alcohol Intake 0.05
Never/Former 318 28.3 22,090 29.5
< 1/week or month 390 34.8 23,667 31.6
1 - < 7/week 260 23.2 19,287 25.8
7+/week 152 13.5 9385 12.5
Unknown 2 0.2 448 0.6
Aspirinα 0.79
Never user 720 64.2 48,194 64.4
Inconsistent user 264 23.5 17,087 22.8
Consistent user 138 12.3 9596 12.8
Diabetes 0.0008
No 1036 92.3 70,837 94.6%
Yes 85 7.6 3972 5.3%
Unknown 1 0.1 68 0.1%
Hysterectomy 0.91
No 677 60.3 45,265 60.5
Yes 445 39.7 29,540 39.5
Unknown 0 0.0 72 0.1
Hormone Replacement Therapy Use < 0.0001
Never 411 36.6 21,419 28.6
Former 238 21.2 14,386 19.2
Current 453 40.4 37,659 50.3
Unknown 20 1.8 1413 1.9
Insurance 0.49
No 34 3.0 2555 3.4
Yes 1076 95.9 71,558 95.6
Unknown 12 1.1 764 1.0
Colonoscopy within 5 years 0.03
None done 546 48.7 34,785 46.5
No 225 20.1 14,018 18.7
Yes 335 29.9 25,068 33.5
Unknown 16 1.4 1006 1.3
Fecal occult blood test within 5 years 0.55
None done 263 23.4 16,841 22.5
No 207 18.4 13,331 17.8
Yes 635 56.6 43,588 58.2
Unknown 17 1.5 1117 1.5
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A positive family history of colorectal cancer in a first-
degree relative was associated with a 34% increase in risk
of colorectal cancer among these women (aHR = 1.34;
95% CI = 1.14, 1.57) with only a marginal increase in the
estimate risk when multiple affected first degree relatives
were reported, but was not statistically significant (aHR =
1.40; 95% CI = 0.92, 2.11) (Table 2). Family history of pros-
tate cancer was not associated with an increase in risk of
colorectal cancer (aHR = 0.94; 95% CI = 0.76, 1.15) after
controlling for colorectal cancer family history. A family
history of both colorectal and prostate cancer was associ-
ated with an almost 50% increase in risk of colorectal can-
cer after adjustment for other important confounding
factors (aHR = 1.48; 95% CI = 1.04, 2.10). Interestingly, risk
of colorectal cancer in African American women with a
family history of colorectal cancer appeared slightly
greater (aHR = 1.80; 95% CI = 1.10, 2.93) compared with
non-Hispanic white women (aHR = 1.31; 95% CI = 1.11,
1.55) (Table 3). And while there was no racial difference in
colorectal cancer risk among women with a family history
of prostate cancer alone (without colorectal cancer),
African American women with a family history of both
prostate and colorectal cancer had an approximate 75%
increase in risk of colorectal cancer (aHR = 1.76; 95% CI =
0.64, 4.81), an estimate greater than for non-Hispanic
white women (aHR = 1.47; 95% CI = 1.00, 2.16). No formal
testing of heterogeneity by race was performed due to the
relatively small number of African American cases.
Table 1 Baseline characteristics of Women Participating in the WHI OS (Continued)
Colorectal cancer cases Non-cases
Characteristic N (%)a N (%)a p-valueb
Family History of Cancerc 0.89
No 639 57.0 42,662 57.0
Yes 435 38.8 28,795 38.5
Unknown 48 4.3 3420 4.6
Median Range Median Range
Age at baseline 66 50–79 63 49–81
Age at diagnosis 74 52–94 – –
Body mass index (kg/m2) 26.8 15.5–66.6 26.0 11.9–69.9
aPercentages may not sum to 100% due to rounding
bChi-square test - excluding missing data
cCancer other than colorectal or prostate among male or female relatives
α Aspirin usage: Consistent - usage of aspirin reported at both initial screening and 3-year follow-up. Inconsistent - at only one of the 2 surveys
Table 2 Baseline reported history of colorectal and prostate cancer among first-degree, full-blood relatives and colorectal cancer risk
in the WHI OS
Family History of cancer
among 1st degree relatives
Colorectal cancer cases Non-cases p-value Crude HR
(95% CI)
Multivariable-
adjusted
HR (95% CI)a
N (%) N (%)
Total (75,999) 1122 1.5 74,877 98.5
Colorectal cancerb <0.001
none 907 80.8 63,678 85.0 referent referent
1 relative 192 17.1 10,071 13.5 1.34 (1.14–1.56) 1.34 (1.14–1.57)
> 1 relative 23 2.0 1128 1.5 1.52 (1.00–2.29) 1.40 (0.92–2.11)
Prostate cancer† 0.999
none 1015 90.5 67,737 90.5 referent referent
1 or more relative 107 9.5 7140 9.5 0.97 (0.80–1.19) 0.94(0.76–1.15)
Colorectal and Prostate cancer <0.001
None 834 74.3 58,053 77.5 referent referent
Colorectal only 181 16.1 9684 12.9 1.30 (1.11–1.53) 1.31 (1.11–1.54)
Prostate only 73 6.5 5625 7.5 0.89 (0.70–1.13) 0.88 (0.67–1.11)
Both 34 3.0 1515 2.0 1.60 (1.14–2.26) 1.48 (1.04–2.10)
aModels include age, race, colonoscopy within 5 years of screening
bModels mutually adjust for colorectal cancer and prostate cancer family history
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Discussion
Our findings suggest that a family history of prostate
cancer alone is not significantly associated with risk of
colorectal cancer. Although the highest risk of colorectal
cancer was observed among women with a family his-
tory of both prostate and colorectal cancer, this estimate
was statistically similar to the observed risk associated
with having a family history of colorectal cancer only.
Nevertheless, the potential for clustering of these tumors
within some families have several implications: 1)
Because of the known contribution of inherited predis-
position for both cancers, the investigation of the clus-
tering of these two cancers within families represents a
unique framework or phenotype to identify new suscep-
tibility genes thus contributing to our knowledge of the
underlying biology of both diseases. 2) Colorectal cancer
is one of the few tumors with effective screening tools
that impact both primary and secondary prevention, so
that identifying and screening high-risk individuals is
critical in reducing both incidence and mortality. 3) It is
well known that communication of colorectal cancer
family history between family members is critical in risk
assessment and making informed decisions about
screening. However, having a complete family history of
all cancers, among close relatives, even among those of
the opposite sex can assist in making these decisions.
These results complement those of a recently pub-
lished study examining familial clustering of breast and
prostate cancer in the WHI. In this study, we observed
that a family history of prostate cancer was associated
with a modest increase in risk (13%) of breast cancer in
the same OS cohort with the highest risk among women
reporting both breast and prostate cancer diagnoses
among first degree relatives. Interestingly, we examined
family history of colorectal cancer and also found a
marginal increase in breast cancer risk (HR = 1.08; 95%
CI = 0.99–1.18) after adjustment for both breast and
prostate cancer diagnosed among relatives [33]. The
reverse relationship was not observed in this study, as
no increase in colorectal cancer risk was observed
among women with a family history of breast cancer
(aHR = 1.00; 95% CI = 0.87–1.15) or women with a family
history of both colorectal and breast cancer (aHR = 1.15;
95% CI = 0.85,1.54).
A family history of colorectal cancer, particularly
among first-degree relatives is an established risk factor
for colorectal cancer, with higher risks observed with a
greater number of affected relatives, and with affected sib-
lings (as opposed to parents) and risk inversely related to
the age at diagnosis among affected relatives [2, 5, 9, 11].
A meta-analysis of 59 studies produced a pooled estimate
of relative risk of 2.24 (95% CI = 2.06, 2.43) associated with
having a single, first-degree relative diagnosed with colo-
rectal cancer, while the estimate associated with having 2
or more affected first-degree relatives was 3.97 (95% CI =
2.60, 6.06) [12]. The same meta-analysis estimated the
cumulative risk of developing colorectal cancer to age 70
among those with a family history (3.6% or 1 in 30),
compared to the general population (1.4% or 1 in 70) with
the absolute risk among individuals with a family history
of colorectal cancer in multiple affected relatives increasing
to 4.1% (or 1 in 24) [12]. These estimates are significantly
higher than what was observed in our study. There are a
couple of potential explanations for this. One explanation
Table 3 Race-specific estimates of colorectal cancer risk associated with family history of colorectal and prostate cancer in the WHI OS
Family History of cancer
among 1st degree relatives
White Black
Colorectal cancer
cases
Non-cases p-
value
Multivariable-
adjusted HR
(95% CI)a
Colorectal cancer
cases
Non-cases p-
value
Multivariable-
adjusted HR
(95% CI)aN (%) N (%) N (%) N (%)
Total (78757) 954 2.0 62,296 98.0 98 2.0 5930 98.0
Colorectal cancer† 0.001 0.033
none 771 80.8 52,807 84.8 referent 77 78.6 5107 86.1 referent
1 or more relatives 183 19.2 9489 15.2 1.31 (1.11–1.55) 21 21.4 823 13.9 1.80 (1.10–2.93)
Prostate cancerb 0.805 0.576
none 859 90.0 56,241 90.3 referent 89 90.8 5280 89.0 referent
1 or more relatives 95 10.0 6055 9.7 0.97 (0.80–1.22) 9 9.2 650 11.0 0.69 (0.33–1.42)
Colorectal and Prostate cancer 0.005 0.146
None 705 73.9 48,010 77.1 referent 72 73.5 4612 77.8 referent
Colorectal only 154 16.1 8231 13.2 1.28 (1.07–1.52) 17 17.3 668 11.3 1.65 (0.97–2.81)
Prostate only 66 6.9 4797 7.7 0.93 (0.72–1.20) 5 5.1 495 8.3 0.51 (0.19–1.41)
Both 29 3.0 1258 2.0 1.47 (1.00–2.16) 4 4.1 155 2.6 1.76 (0.64–4.81)
aModels include age, colonoscopy within 5 years of baseline
bModels mutually adjust for colorectal and prostate cancer family history
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for this discrepancy may stem from the fact that the vast
majority of studies included in the meta-analysis are case-
control or cross-sectional (43 of 59) as opposed to cohort
and therefore subject to different sensitivity in reporting of
family history between cancer cases and controls. Further-
more, only 4 of 17 cohort studies providing data for this
meta-analysis had cases which were ascertained prospect-
ively. The remaining studies compared the incidence of
colorectal cancer in relatives of colorectal cancer cases with
what might be expected from the general population. The
difference might also be explained by the fact that
family history of cancer was assessed only at baseline
in the WHI cohort, so that additional cancers diag-
nosed among family members post-baseline were not
captured in this analysis [34].
Fewer studies have examined risk of colorectal cancer
associated with a family history of other cancers includ-
ing prostate cancer [21–23, 26]. An excess of endomet-
rial cancer in Lynch syndrome families has been widely
reported with a 40–60% lifetime risk of diagnosis [35].
Cancers of the stomach, small bowel, pancreas, and
ovary have also been reported with less frequency in
HNPCC families [14]. In a pooled analysis of case-
control studies, Turati et al. observed an increased risk
of colorectal cancer associated with a family history of
prostate cancer that was similar to the current investiga-
tion (ORpooled = 1.6) with higher estimates if the proband
was diagnosed younger than age 60 (ORpooled = 2.1).
Similarly, an increased risk of prostate cancer was ob-
served to be associated with a family history of colorectal
cancer (ORpooled = 1.5) [21]. Other studies report no sig-
nificant association between colorectal cancer and family
history of prostate cancer or vice-versa [3, 22–24].
To our knowledge, this is the first investigation to
examine familial aggregation of colorectal and prostate
cancer in a racially-diverse population and to explore
the possibility that the risk relationship differs by race.
The number of African American cases (n = 98) limited
our ability to formally test for differences in estimates of
risk related to family history, however our results gener-
ally suggest that African American women with a family
history of colorectal cancer and of both colorectal and
prostate cancer have a greater risk of being diagnosed
with colorectal cancer compared with non-Hispanic
white women. These findings, if replicated in a larger
minority sample, are particularly important in that stud-
ies have shown that only 30–60% of individuals with a
family history of colorectal cancer adhere to screening
guidelines [36, 37], with some evidence to suggest that
African Americans and Hispanics with a positive family
history were less likely than whites to adhere to screen-
ing recommendations [36, 38].
The strengths of the current investigation include its
relatively large population which allowed for precise
estimation of colorectal cancer risk associated with a
history of colorectal and prostate cancer among immedi-
ate family members, and particularly among those with a
family history of both cancers, which is a relatively rare
in the general population (~2%). Additionally, the pro-
spective nature of the WHI cohort eliminates the poten-
tial for misclassification bias produced by differential
recall of family history in colorectal cancer cases com-
pared to non-cases. Other important strengths include
the long period of follow-up for outcome with central
adjudication of colorectal cancers. Study limitations in-
clude the small number of African American women
with colorectal cancer in the study as well as the reliance
on self-report of family history of cancer. Evidence
suggests that self-reported cancer family history among
first-degree relatives is generally accurate [39].
Conclusions
In summary, family histories of both colorectal and
prostate cancer and colorectal cancer only were
associated with the risk of colorectal cancer in women
diagnosed after age 50. However, there was no increase
in risk associated with having only a family history of
prostate cancer, absent colorectal cancer. There was
some suggestion that African American women with
a positive family history were at a greater risk com-
pared with non-Hispanic whites, a finding deserving
further study with a larger number of minorities given
the racial disparities in colorectal cancer incidence
and mortality.
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